YAG Intrinsic Valuation and Fundamental Analysis - Atossa Therapeutics Inc

	Atossa Therapeutics Inc F:YAG	US
S	Singapore Telecommunications Ltd XMUN:SIT4	SG

Intrinsic Value

The intrinsic value of Atossa Therapeutics Inc (YAG) under the Base Case is 0.2 EUR per share. Compared with the current market price of 0.2 EUR, the stock appears Fairly Valued .

The intrinsic value is calculated using the DCF method.

Do our valuations actually work? See backtest results .

YAG Intrinsic Value

Fairly Valued

Intrinsic Value

Price €0.2

Track Buy Zone

20% below Intrinsic Value €0.16

Get notified when the price drops into your buy zone

Intrinsic Value €0.2

Current Price €0.2

Margin of Safety 20% €0.16

Or choose another margin of safety

0% below Intrinsic Value

10% below Intrinsic Value

30% below Intrinsic Value

40% below Intrinsic Value

50% below Intrinsic Value

Custom

Fundamental Analysis

What Atossa Therapeutics Does

Biotechnology Health Care

Atossa Therapeutics is a clinical-stage drug developer focused on breast cancer and other breast health conditions. The company works on treatments meant to be taken by patients, with a pipeline centered on medicines that can reduce cancer risk, treat early disease, or help in combination with other therapies. It does not sell consumer products; its business is built around advancing drug candidates through research and clinical testing.

Headquarters: United States of America US
Employees: 16
IPO date: Nov 8, 2012

Read the full company overview

How Atossa Therapeutics makes money

Breast cancer drugs

Atossa Therapeutics develops medicines for breast cancer, including treatments aimed at reducing tumor growth and helping doctors manage the disease. Its work is centered on testing these drug candidates in clinical trials and moving them toward regulatory approval.

Customers: Oncology patients, cancer doctors, and hospitals that would use the medicines if they are approved; clinical trial sites support the development work before approval.
Revenue Model: The company plans to earn money by selling approved prescription drugs through the pharmaceutical supply chain, and may also use licensing or partnership deals around its drug candidates.

View Company Overview